申请人:Daiichi Sankyo Company, Limited
公开号:US20140073622A1
公开(公告)日:2014-03-13
To develop an antibiotic having a novel mechanism of action, the present inventors have searched for a compound that has weak cytotoxicity, the physical property of high solubility in water, the effect of inhibiting both DNA gyrase GyrB and topoisomerase IV ParE subunits, and sufficient antibacterial activity. As a result, the present inventors have completed the present invention by finding that a compound of the present invention represented by the general formula (1), a pharmacologically acceptable salt thereof, and a prodrug thereof have desirable properties. The present invention provides a pharmaceutical composition (particularly, a preventive or therapeutic composition for infectious disease) comprising a compound represented by the formula (1), a pharmacologically acceptable salt thereof, or a prodrug thereof as an active ingredient.
为了开发一种具有新型作用机制的抗生素,本发明者寻找具有以下特点的化合物:细胞毒性较弱、在水中溶解度高、能够抑制DNA旋转酶GyrB和拓扑异构酶IV ParE亚基,以及具有足够的抗菌活性。结果,本发明者通过发现本发明的一般式(1)所表示的化合物、其药理学可接受的盐和前药具有理想的特性来完成了本发明。本发明提供了一种药物组合物(特别是用于预防或治疗传染病的组合物),其包括由公式(1)所表示的化合物、其药理学可接受的盐或前药作为活性成分。